A. Rush

690. Impact of VNS on symptoms, function, and quality of life in patients with markedly treatment-resistant depression: findings from the US RECOVER study

Abstract Background Treatment-resistant depression (TRD), characterized by marked symptom burden and poor daily function and quality of life (QoL), remains a major clinical challenge. Greater degrees of treatment resistance (more failed trials) are associated with lower rates of initial benefit and higher rates of rela...

661. Vagus nerve stimulation reduces suicidal ideation in markedly treatment-resistant depression: RECOVER findings

Abstract Background Individuals with markedly treatment-resistant depression (mTRD) have substantial risk for suicide attempt and completion. Few antidepressant treatments offer benefit for suicide, and it is critical that novel treatments not increase/worsen suicidal ideation (SI) or behavior. Aims & Objectives Assess...

Durability of Implanted Cervical Vagus Nerve Stimulation in Treatment-resistant Major Depression: Summary of Findings and Potential Mechanisms of Action

655. Toward a brief, sensitive tool to assess depressive symptom outcomes in research and clinical practice: lessons from the RECOVER trial

Abstract Background In RECOVER, a 12-month, double-blind, randomized, controlled trial (RCT) comparing active versus sham adjunctive vagus nerve stimulation (VNS) in persons with markedly treatment-resistant depression (mTRD), total scores on the Quick Inventory of Depressive Symptomology–Clinician (QIDS-C) and –Self-R...

The RECOVER Trial of Vagus Nerve Stimulation in Markedly Treatment-Resistant Depression: Critical Findings, Lessons Learned, and Future Directions.

This review summarizes the RECOVER trial's key findings and their clinical and research implications. RECOVER was a 12-month triple-blind randomized trial in adults with markedly treatment-resistant major depressive disorder (N=493; at least four failed trials in the current episode) that compared adjunctive active and...

What are the clinical implications of mixed features in major depressive disorder? A VAST-D report.

Mixed features were highly prevalent and associated with greater clinical burden, and Assessment of mixed features may provide clinically relevant information when selecting next-step pharmacologic strategies, particularly when considering a switch to bupropion sustained release.